Author | Age (mean ± SD) | Sex (F/M) | BMI (kg/m2) | Duration diabetes | Follow-up/years |
---|---|---|---|---|---|
Chong et al. 2017 [31] | 48.2 ± 8.4 | 46/71 | 32.4 ± 1.6 | 8.25 ± 5.05 | Two |
Courcoulas et al. 2020 [32] | 46.55 ± 7.25 vs. 48.9 ± 4.7 | 33/41 vs. 17/20 | 35.56 ± 3.05 vs. 35.7 ± 3.3 | 6.85 ± 4.45 vs. 5.7 ± 5.6 | Five |
Ding et al. 2015 [33] | 50.6 ± 12.6 vs. 51.4 ± 7.5 | 9/18 vs. 9/22 | 36.4 ± 3.0 vs. 36.7 ± 4.2 | Not mentioned | One |
Foschi et al. 2019 [34] | 50.6 ± 1.9 vs. 55.0 ± 1.5 | 22/30 vs. 22/30 | 43.0 ± 1.5 vs. 41.9 ± 1.2 | 4.4 ± 0.6 vs. 4.4 ± 0.7 | Five |
Halperin et al. 2014 [35] | 50.7 ± 7.6 vs. 52.6 ± 4.3 | 13/19 vs. 10/19 | 36.0 ± 3.5 vs. 36.5 ± 3.4 | 10.6 ± 6.6 vs. 10.2 ± 6.1 | One |
Kashyap et al. 2013 [36] | 47.9 ± 9.85 vs. 50 ± 8.4 | 24/37 vs. 8/17 | 36.25 ± 2.9 vs. 35.8 ± 3.0 | 7.5 ± 4.75 vs. 10.5 ± 5.0 | Two |
Kirwan et al. 2022 [37] | 49 ± 9 vs. 52 ± 7 | 137/195 vs. 75/121 | 37 ± 4 vs. 37 ± 3 | 9 ± 6 vs. 9 ± 6 STAMPEDE, TRIABETES, SLIMM-T2D, and CROSSROADS trials | Three |
Mingrone et al. 2021 [39] | 20/34 relapse |  |  ≥ 35 |  > 5 years | 10 years |
Parikh et al. 2014 [40] | 46.8 ± 8.1 vs. 53.9 ± 8.4 | 23/29 vs. 22/28 | 32.8 ± 1.7 vs. 32.4 ± 1.8 | NA | 6 months |
Simonson et al. 2018 [41] | 50.7 ± 7.6 vs. 52.6 ± 4.3 | 13/19 vs. 10/19 | 36.3 ± 3.4. 6/19 vs. 7/19 < 35 | 10.6 ± 6.6 vs. 10.2 ± 6.1 | Three |
Sjöholm et al. 2022 [42] | 48.6 ± 6.0 vs. 50.5 ± 6.3 | 236/393 vs. 182/308 | 42.4 ± 4.9 vs. 40.1 ± 4.7 | NA | 10 years |